Evolving concepts and techniques for anti-doping

Bioanalysis

Volumn 4, Issue 13, 2012, Pages 1667-1680

  Friedmann, Theodore ^a   Flenker, Ulrich ^b   Georgakopoulos, Costas ^c   Alsayrafi, Mohammed ^c   Sottas, Pierre Edouard ^d   Williams, Stephen A ^e   Gill, Rosalynn D ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^c Anti Doping Laboratory ^*  (Qatar)

^d Maison du Sport International   (Switzerland)

^e SomaLogic Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; APTAMER; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHORIONIC GONADOTROPIN; ERYTHROPOIETIN; REAGENT;

BLOOD SAMPLING; CHEMICAL ANALYSIS; DOPING; FALSE POSITIVE RESULT; GAS CHROMATOGRAPHY; ISOTOPE ANALYSIS; LABORATORY TEST; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; MOLECULAR GENETICS; QUALITY CONTROL; REVIEW; SENSITIVITY AND SPECIFICITY; SPORTS ORGANIZATION;

APTAMERS, NUCLEOTIDE; ATHLETIC PERFORMANCE; BIOLOGICAL ASSAY; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPING IN SPORTS; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GENETIC ENHANCEMENT; HUMANS; INTERNATIONAL COOPERATION; MALE; PHARMACEUTICAL PREPARATIONS; SUBSTANCE ABUSE DETECTION;

EID: 84864434197     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.12.146     Document Type: Review

References (73)

1. Georgakopoulos CG, Vonaparti A, Stamou M et al. Preventive doping control analysis: Liquid and gas chromatography time of flight mass spectrometry for designer steroids detection. Rapid Comm. Mass Spectrom. 21, 2439-2446 (2007).
2. Kiousi P, Angelis YS, Lyris E et al. Two-step silylation procedure for the unified analysis of 190 doping control substances in human urine samples by GC-MS. Bioanalysis 1, 1209-1224 (2009).
3. Donike M, Zimmermann J. Preparation of trimethylsilyl, triethylsilyl and tert-butyldimethylsilyl enol ethers of ketosteroids for investigations by gas-chromatography and mass-spectrometry. J. Chromatogr. 202, 483-486 (1980).
4. Vonaparti A, Lyris E, Angelis YS et al. Preventive doping control screening analysis of prohibited substances in human urine using rapid resolution liquid chromatography-high resolution time of flight mass spectrometry. Rapid Comm. Mass Spectrom. 24, 1595-1609 (2010).
5. Peters RJB, Stolker AAM, Mol JGJ et al. Screening in veterinary drug analysis and sports doping control based on full-scan accurate mass spectrometry. Trends Anal. Chem. 29, 1250-1268 (2010).
6. Catlin DH, Sekera MH, Ahrens BD, Starcevic B, Chang Y-C, Hatton CK. Tetrahydrogestrinone: Discovery, synthesis, and detection in urine. Rapid Comm. Mass Spectrom. 18, 1245-1249 (2004).
7. Sekera M, Ahrens B, Chang Y, Starcevic B, Georgakopoulos C, Catlin D. Another designer steroid: Discovery, synthesis and detection of MADOL in urine. Rapid Comm. Mass Spectrom. 19, 781-784 (2005).
8. Schänzer W, Geyer H, Fusshöller G et al. Mass spectrometric identification and characterization of a new long-term metabolite of metandienone in human urine. Rapid Comm. Mass Spectrom. 20, 2252-2258 (2006).
9. Sobolevsky T, Rodchenkov G. Detection and mass spectrometric characterization of novel long-term dehydrochloromethyltestosterone metabolites in human urine. J. Steroid Biochem. Mol. Biol. 128, 121-127 (2012).
10. Peters RJB, Van Engelen MC, Touber ME, Georgakopoulos C, Nielen MWF. Searching for in silico predicted metabolites and designer modifications of (cortico)steroids in urine by high resolution liquid chromatography time-of-flight mass spectrometry. Rapid Comm. Mass Spectrom. 23, 2329-2337 (2009).
11. Fragkaki AG, Tsantili-Kakoulidou A, Angelis YS, Koupparis M, Georgakopoulos C. Gas chromatographic quantitative structure- retention relationships of trimethylsilylated anabolic androgenic steroids by multiple linear regression and partial least squares. J. Chromatogr. A 1216, 8404-8420 (2009).
12. Fragkaki AG, Angelis YS, Tsantili-Kakoulidou A, Koupparis M, Georgakopoulos C. Schemes of metabolic patterns of anabolic androgenic steroids for the estimation of metabolites of designer steroids in human urine. J. Steroid Biochem. Mol. Biol. 115, 44-61 (2009).
13. Fragkaki A, Angekis Y, Tsantili-Kakoulidou A, Koupparis M, Georgakopoulos C. Statistical analysis of fragmentation patterns of electron ionization mass spectra of enolized-trimethylsilylated anabolic androgenic steroids. Int. J. Mass Spectrom. 285, 58-69 (2009).
14. Tsivou M, Georgakopoulos DG, Dimopoulou HA, Koupparis MA, Atta-Politou J, Georgakopoulos CG. Stabilization of human urine doping control samples: A current opinion. Anal. Bioanal. Chem. 401, 553-561 (2011).
15. Blackledge RD. Bad science. The instrumental data in the Floyd Landis case. Clin. Chim. Acta 406(1-2), 8-13 (2009).
16. Meier-Augenstein W, Brand W, Hoffmann GF, Rating D. Bridging the information gap between isotope ratio mass spectrometry and conventional mass spectrometry. Biol. Mass Spectrom. 23(6), 376-378 (1994).
17. Meier-Augenstein W. On-line recording of 13C/12C ratios and mass spectra in one gas chromatographic analysis. J. High. Resolut. Chromatogr. 18(1), 28-32 (1995).
18. Muccio Z, Jackson GP. Simultaneous identification and d13C classification of drugs using GC with concurrent single quadrupole and isotope ratio mass spectrometers. J. Forensic Sci. 56(S1), S203-S209 (2011).
19. McIntyre CP, Galutschek E, Roberst ML, von Reden KF, McNichol AP, Jenkins WJ. A continous-flow gas chromatography 14C accelerator mass spectrometry system. Radiocarbon 52(2), 295-300 (2010).
20. Tuniz C, Zoppi U, Hotchkis MAC. Sherlock Holmes counts the atoms. Nucl. Instr. Meth. Phys. B 213, 469-475 (2004).
21. Flenker U, Hebestreit M, Piper T, Schänzer W. A new, effective, and robust method to couple gas chromatography and isotope ratio mass spectrometry. In: RECENT advances in doping analysis (14): PROCEEDINGS of the Manfred Donike Workshop, 24th Cologne Workshop on Dope Analysis, 4th to 9th June 2006. W Schänzer, H Geyer, A Gotzmann, U Mareck (Eds). Sport & Buch Strauβ, Köln, Germany, 299-306 (2006).
22. Flenker U, Hebestreit M, Piper T, Hülsemann F, Schänzer W. Improved performance and maintenance in gas chromatography-isotope ratio mass spectrometry by precolumn solvent removal. Anal. Chem. 79, 4162-4168 (2007).
23. Sacks GL, Zhang Y, Brenna JT. Fast gas chromatography combustion isotope ratio mass spectrometry. Anal. Chem. 79(16), 6348-6358 (2007).
24. Tobias HJ, Zhang Y, Auchus RJ, Brenna JT. Detection of synthetic testosterone use by novel comprehensive two-dimensional gas chromatography combustion-isotope ratio mass spectrometry. Anal. Chem. 83, 7158-7165 (2011).
25. Hebestreit M, Flenker U, Fusshöller G et al. Determination of the origin of urinary norandrosterone traces by gas chromatography combustion isotope ratio mass spectrometry. Analyst 13, 1021-1026 (2006).
26. Piper T, Geyer H, Gougoulidis V, Flenker U, Schänzer W. Determination of 13C/12C ratios of urinary excreted boldenone and its main metabolite 5b-androst-1-en-17b-ol-3-one. Drug Test. Anal. 2(5), 217-224 (2010).
27. Piper T, Fusshöller G, Emery C, Schänzer W, Saugy M. Investigations on carbon isotope ratios and concentrations of urinary formestane. Drug Test. Anal. doi:10.1002/dta.386 (2012) (Epub ahead of print).
28. Güntner U, Flenker U, Ayotte C, Ueki M, Schänzer W. D/H isotope analysis of endogenous steroids - first results. In: RECENT advances in doping analysis (12). Proceedings of the Manfred Donike Workshop, 22nd Cologne Workshop on Dope Analysis, 7th to 12th March 2004. W Schänzer, H Geyer, A Gotzmann, U Mareck (Eds). Sport & Buch Strauβ, Köln, Germany, 251-259 (2004).
29. Güntner U, Flenker U, Geyer H, Ueki M, Ayotte C, Schänzer W. Measurement of D/H and 13C/12C in endogenous steroids can reveal transdermal application of testosterone. Presented at: THE Joint European Stable Isotope Users Meeting, (JESIUM). Vienna, Austria, 30 August-3 September 2004.
30. Güntner U. Änderungen von Isotopenverhältnissen (13C/12C;D/H) in urinären Steroiden nach transdermaler Applikation von Testosteron. Master's thesis, Deutsche Sporthochschule, Köln, Germany (2004).
31. Piper T, Thomas A, Thevis M, Saugy M. Investigations on hydrogen isotope ratios of endogenous urinary steroids: Reference population based thresholds and proof of principal. Presented at: THE Manfred Donike Workshop 2012. 30th Cologne Workshop on Dope Analysis. Cologne, Germany, 26 February-2 March 2012.
32. Flenker U, Hülsemann F, Gougoulidis V, Sigmund G, Schänzer W. Elucidation of original and metabolic sources of ephedrines by stable isotope analysis. In: RECENT advances in doping analysis (15). Proceedings of the Manfred Donike Workshop, 25th Cologne Workshop on Dope Analysis, 25th February to 2nd March 2009. W Schänzer, H Geyer, A Gotzmann, U Mareck (Eds). Sport & Buch Strauβ, Köln, Germany, 209-216 (2009).
33. Thomas A, Beuck S, Eickhoff JC et al. Quantification of urinary AICAR concentrations as a matter of doping controls. Anal. Bioanal. Chem. 396, 2899-2908 (2010).
34. De Groot P. Handbook of Stable Isotope Analytical Techniques, Volume 1. Elsevier, Amsterdam, The Netherlands (2004).
35. De Groot P. Handbook of Stable Isotope Analytical Techniques, Volume 2. Elsevier, Amsterdam, The Netherlands (2009).
36. Alario J, Perez M, Vazquez A, Villen J. Very-large-volume sampling of water in gas chromatography using the through oven transfer adsorption desorption (TOTAD) interface for pesticide-residue analysis. J. Chromatogr. Sci. 39, 65-69 (2001).
37. Toledano R, Gea S, Díaz-Plaza E, Vázquez A, Villén J, Munoz-Guerra H. Analysis of steroids by on line coupling LC-TOTAD- GC with a fraction collector using MS and C-IRMS detectors. Presented at: MANFRED Donike Workshop 2012. 30th Cologne Workshop on Dope Analysis. Cologne, Germany, 26 February-2 March 2012.
38. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: rna ligands to bacteriophage T4 DNA polymerase. Science 249, 505-510 (1990).
39. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 36, 818-822 (1990).
40. Vaught JD, Bock C, Carter J et al. Expanding the chemistry of DNA for in vitro selection. J. Am. Chem. Soc. 132, 4141-4151 (2010).
41. Gold L, Ayers D, Bertino J et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 5, 12 (2010).
42. Kraemer S, Vaught JD, Bock C et al. From SOMAmer™-based biomarker discovery to diganostic and clinical applications: A SOMAmer-based streamlined multiplex proteomic assay. PLoS One 6, 10 (2011).
43. Ostroff RM, Bigbee WL, Franklin W et al. Unlocking biomarker discovery: Large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One 5, 12 (2010).
44. Eaton BE. The joys of in vitro selction: Chemically dressing oligonucleotides to satiate protein targets. Curr. Opin. Chem. Biol. 1, 10-16 (1997).
45. Dewey T, Mundt A, Crouch G, Zyniewski M, Eaton B. New uridine derivatives for systematic evolution of RNA ligands by exponential enrichment. J. Am. Chem. Soc. 117, 8474-8475 (1995).
46. Bruno JG, Carrillo MP, Phillips T, Edge A. Discrimination of recombinant from natural human growth hormone using DNA aptamers. J. Biomol. Tech. 22(1), 27-36 (2011).
47. Williams S, Ostroff R, Brody E et al. Exposing the criminal record of every blood sample: Use of SOMAmer™ technology and sample mapping vectors to mitigate false biomarker discoveries in lung cancer. Presented at: 2012 ASCO Annual Meeting. Chicago, IL, USA, 4-6 June 2012.
48. Bowers LD. The analytical chemistry of drug monitoring in athletes. Annu. Rev. Anal. Chem. 2, 485-507(2009).
49. Thevis M, Thomas A, Schänzer W. Current role of LC-MS(/MS) in doping control. Anal. Bioanal. Chem. 401(2), 405-420 (2011).
50. Ho KK, Nelson AE. Growth hormone in sports: Detecting the doped or duped. Horm. Res. Paediatr. 76(Suppl.) 84-90 (2011).
51. Catlin DH, Sekera MH, Ahrens BD, Starcevic B, Chang YC, Hatton CK. Tetrahydrogestrinone: Discovery, synthesis, and detection in urine. Rapid Commun. Mass Spectrom. 18(12), 1245-049 (2004).
52. Pusztai L. Current status of prognostic profiling in breast cancer. Oncologist 13(4), 350-360 (2008).
53. Friedmann T, Rabin O, Frankel MS. Ethics. Gene doping and sport. Science 327(5966), 647-648 (2010).
54. Bhasker CR, Friedmann T. Insulin-like growth factor-1 coordinately induces the expression of fatty acid and cholesterol biosynthetic genes in murine C2C12 myoblasts. BMC Genomics 9, 535 (2008).
55. Neuberger EW, Moser DA, Simon P. Principle considerations for the use of transcriptomics in doping research. Drug Test. Anal. 3(10), 668-675 (2011).
56. Schönfelder M, Hofmann H, Anielski P, Thieme D, Oberhoffer R, Michna H. Gene expression profiling in human whole blood samples after controlled testosterone application and exercise. Drug Test. Anal. 3(10), 652-660 (2011).
57. Beiter T, Zimmermann M, Fragasso A et al. Direct and long-term detection of gene doping in conventional blood samples. Gene Ther. 18(3), 225-231 (2011).
58. Ni W, Le Guiner C, Gernoux G, Penaud- Budloo M, Moullier P, Snyder RO. Longevity of rAAV vector and plasmid DNA in blood after intramuscular injection in nonhuman primates: Implications for gene doping. Gene Ther. 18(7), 709-718 (2011).
59. Mitchell CJ, Nelson AE, Cowley MJ et al. Detection of growth hormone doping by gene expression profiling of peripheral blood. J. Clin. Endocrinol. Metab. 94(12), 4703-4709 (2009).
60. Labrie F, Luu-The V, Calvo E et al. Tetrahydrogestrinone induces a genomic signature typical of a potent anabolic steroid. J. Endocrinol. 184(2), 427-433 (2005).
61. Sottas PE, Robinson N, Rabin O, Saugy M. The athlete biological passport. Clin. Chem. 57(7), 969-976 (2011).
62. Harris EK. Statistical principles underlying analytic goal-setting in clinical chemistry. Am. J. Clin. Pathol. 374, 72-82 (1979).
63. Fraser CG. Interpretation of Clinical Chemistry Laboratory Data. Blackwell Science Ltd, Oxford, UK (1986).
64. Sottas PE, Baume N, Saudan C, Schweizer C, Kamber M, Saugy M. Bayesian detection of abnormal values in longitudinal biomarkers with an application to T/E ratio. Biostatistics 8(2), 285-296 (2007).
65. Ricos C, Alvarez V, Cava F et al. Current databases on biologic variation: Pros, cons and progress. Scand. J. Clin. Lab. Invest. 59, 491-500 (1999).
66. Sottas PE, Saugy M, Saudan C. Endogenous steroid profiling in the athlete biological passport. Endocrinol. Metab. Clin. North Am. 39, 59-73 (2010).
67. Sottas PE, Saudan C, Schweizer C, Baume N, Mangin P, Saugy M. From population-to subject-based limits of T/E ratio to detect testosterone abuse in elite sports. Forensic Sci. Int. 174, 166-172 (2008).
68. Baraniuk RG. More is less: Signal processing and the data deluge. Science 331(6018), 717-719 (2011).
69. Topol E. The creative destruction of medicine: How the digital revolution will create better health care. Basic Books, NY, USA (2012).
70. Sottas PE, Robinson N, Giraud S et al. Statistical classification of abnormal blood profiles in athletes. Int. J. Biostatistics 2(1), 3 (2006).
71. Van Renterghem P, Van Eenoo P, Sottas PE, Saugy M, Delbeke F. A pilot study on subject-based comprehensive steroid profiling: Novel biomarkers to detect testosterone misuse in sports. Clin. Endocrinol. 75, 134-140 (2011).
72. Hopfield JJ. Neural networks and physical systems with emergent collective computational abilities. Proc. Natl Acad. Sci. 1982 79(8), 2554-2558 (1982).
73. Reichel C. Omics-strategies and methods in the fight against doping. Forensic Sci. Int. 213(1-3), 20-34 (2011).